Global Depression Treatment Therapy Market Valued at $12.6 Billion in 2025, Growing at a CAGR of 5.1%

Global depression treatment therapy market was valued at $12.6 billion in 2025 and is growing at a CAGR of 5.1% during the forecast period (2026-2035). The market growth is driven by rising mental health awareness, increasing prevalence of depression, technological advances (telehealth, AI), and investment in novel therapies, while facing challenges like high costs, stigma, and treatment resistance, with a growing focus on personalized medicine, combination therapies, and digital solutions. Key factors include increasing patient demand, pharmaceutical innovation, and supportive healthcare policies, but are hindered by treatment access barriers, lack of standardized diagnosis, and persistent social stigma.

Browse the full report description of “Depression Treatment Therapy Market Size, Share & Trends Analysis by Treatment Type (Pharmacological Treatments, Psychotherapy, Device-Based Treatments, Combined Treatment, and Others), by Disease Indication (Major Depression, Bipolar Depression, Seasonal Affective Disorder (SAD), Premenstrual Dysphoric Disorder (PMDD), and Others), and by Distribution Channel (Hospitals, Specialty Clinics, Retail Pharmacies, Drug Stores, and E-Commerce) Forecast Period (2026-2035)” at https://www.omrglobal.com/industry-reports/depression-treatment-market

Moreover, the rising prevalence of major depressive disorder globally, coupled with millions of adults facing treatment-resistant depression, is propelling market growth. For instance, in January 2026, the FDA approved the FL-100, the first at-home brain-stimulation device for treating moderate to severe major depressive disorder (MDD). This device, designed for adults aged 18 and older, provides low-intensity transcranial direct-current stimulation (tDCS) to stimulate the prefrontal cortex. A trial showed that participants using the device experienced an average of 58% improvement in depression symptoms after 10 weeks. With around 21 million adults in the US suffering from depression and many not responding well to traditional medications, the FL-100 offers a new therapeutic option. It is expected to be available in the US by the second quarter of 2026, potentially transforming how depression is treated.

Leading Companies Contributing to Advancements in Depression Treatment Therapies

The depression treatment therapy market comprises several established pharmaceutical and healthcare companies, including Eli Lilly and Co., GlaxoSmithKline plc, Johnson & Johnson, and Pfizer Inc., among others. These organizations are actively involved in the development and adoption of a broad range of therapeutic and supportive solutions. Their efforts include investments in digital health technologies such as telemedicine platforms, electronic health records, remote patient monitoring systems, and AI-enabled clinical tools, which collectively support more efficient and data-driven approaches to mental healthcare delivery at a global level.

• In December 2025, the FDA approved the FL-100 headset, the first at-home nondrug treatment for depression, developed by Flow Neuroscience. This wearable device is authorized for use alone or alongside medications for adults with moderate to severe major depressive disorder. The headset utilizes transcranial direct stimulation to apply a gentle electric current to the prefrontal cortex, a brain region often underactive in individuals with depression, affecting over 20 million adults in the U.S.
• In January 2025, SPRAVATO (esketamine) received US FDA approval as the first and only monotherapy for adults with treatment-resistant depression (TRD). The approval follows a Priority Review and is based on data showing that SPRAVATO met its primary endpoint of rapid and superior improvement in depressive symptoms compared to a placebo, as early as 24 hours after administration. In a randomized controlled study, it showed significant improvement on the Montgomery-Asberg Depression Rating Scale (MADRS), with 22.5% of patients achieving remission at week 4, compared to 7.6% for placebo. SPRAVATO®'s safety profile remained consistent with previous data, posing no new concerns.
• In September 2024, Abbott launched the TRANSCEND study, a double-blind, randomized, sham-controlled clinical trial, to evaluate its deep brain stimulation (DBS) device for difficult-to-treat depression. The trial will include 100 participants who have failed at least four previous treatments. This announcement follows Abbott receiving a Breakthrough Device designation from the FDA, which facilitates expedited regulatory review for technologies aimed at serious ailments.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
  • By Treatment Type
  • By Disease Indication
  • By Distribution Channel
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape - Eli Lilly and Co., GlaxoSmithKline plc, Johnson & Johnson, Johnson & Johnson, Pfizer Inc., among others.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Depression Treatment Therapy Market Report Segment

By Treatment Type

• Pharmacological Treatments
• Psychotherapy
• Device-Based Treatments
• Combined Treatment
• Others

By Disease Indication

• Major Depression
• Bipolar Depression
• Seasonal Affective Disorder (SAD)
• Premenstrual Dysphoric Disorder (PMDD)
• Others

By Distribution Channel

• Hospitals
• Specialty Clinics
• Retail Pharmacies
• Drug Stores
• E-commerce

Global Depression Treatment Therapy Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/depression-treatment-market